title: [A retrospective, observational and multicentre study on patients with hyperactive bladder on treatment with mirabegron and oxybutinine under usual clinical practice conditions].
abstract: OBJECTIVE
  To evaluate therapeutic persistence, healthcare resources, medical costs and adverse events of oxybutynin and mirabegron treatments in patients with overactive bladder in routine medical practice.
  
  
  METHODS
  An observational, retrospective, multicentre study was carried out using the records of patients attended to in 3 different geographic locations (Barcelona, Girona, Asturias). An analysis was made on the 2 study groups (oxybutynin and mirabegron). Follow-up time was one year. Persistence was defined as the time (months), without discontinuation of the initial treatment, or without change of treatment at least 60 days after the initial prescription. Primary endpoints: comorbidity, healthcare resources used, and adverse events. The data was analysed using the SPSSWIN Program, with a significance of P<.05.
  
  
  RESULTS
  Of the total of1,277 patients included in the study, 42.9% were on oxybutynin and 57.1% mirabegron. The mean age was 69.3 years and 53.2% were female. Demographic characteristics and morbidity were similar between the drugs and had a similar persistence (35.0% oxybutynin vs. 32.2% mirabegron, P=.294), although their costs were lower (1,151.2 vs. €1,809.6, P<.001). The biggest differences were observed in the price of medication (279.2 vs. €692.3, P<.001; a variation of: -€413.1); and adverse events (9.7 vs. 4.9%, P<.001).
  
  
  CONCLUSIONS
  Patients treated with oxybutynin vs. mirabegron for overactive bladder had similar persistence with the treatment, lower healthcare costs, but with higher oxybutynin vs. mirabegron adverse reaction rates.
authors.affiliation: Equipo de Atención Primaria, La Roca del Vallès, Barcelona, España. Electronic address: asicras@bsa.cat.
authors.forename: A
authors.initials: A
authors.lastname: Sicras-Mainar
authors.affiliation: Documentación Médica, Hospital Germans Trias i Pujol, Badalona, Barcelona, España.
authors.forename: R
authors.initials: R
authors.lastname: Navarro-Artieda
authors.affiliation: Gerencia de Atención Primaria, Mallorca, España.
authors.forename: A
authors.initials: A
authors.lastname: Ruiz-Torrejón
authors.affiliation: Research Group on Statistics, Econometrics and Health (GRECS), Universidad de Girona, Girona, España; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, España.
authors.forename: M
authors.initials: M
authors.lastname: Saez
authors.affiliation: Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, España; Unitat de Suport a la Recerca, Institut d'Investigació en Atenció Primària (IDIAP) Jordi Gol, Girona, España.
authors.forename: G
authors.initials: G
authors.lastname: Coll-de Tuero
authors.affiliation: Atención Primaria, Avilés, Asturias, España.
authors.forename: L
authors.initials: L
authors.lastname: Sánchez
mesh_terms: D000083:Acetanilides / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D017048:Health Care Costs; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D055118:Medication Adherence; D008875:Middle Aged; D012189:Retrospective Studies; D013030:Spain; D013844:Thiazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000191:economics; D064804:Urological Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D055815:Young Adult
chemical_list: D000083:Acetanilides; D008333:Mandelic Acids; D013844:Thiazoles; D064804:Urological Agents; C005419:oxybutynin; C520025:mirabegron
keywords: Costes sanitarios; Healthcare costs; Healthcare resources; Mirabegron; Mirabegrón; Overactive bladder; Oxibutinina; Oxybutynin; Persistence; Persistencia; Uso de recursos; Vejiga hiperactiva